We are live on ! Find out more
URGN icon

UroGen Pharma
URGN

63 hedge funds and large institutions have $413M invested in UroGen Pharma in 2018 Q4 according to their latest regulatory filings, with 9 funds opening new positions, 25 increasing their positions, 19 reducing their positions, and 15 closing their positions.

New
Increased
Maintained
Reduced
Closed

32% more repeat investments, than reductions

Existing positions increased: 25 | Existing positions reduced: 19

0% more funds holding in top 10

Funds holding in top 10: 3 → 3 (0)

3.07% less ownership

Funds ownership: 62.61% → 59.54% (-3.1%)

11% less funds holding

Funds holding: 71 → 63 (-8)

12% less capital invested

Capital invested by funds: $469M → $413M (-$55.9M)

40% less first-time investments, than exits

New positions opened: 9 | Existing positions closed: 15

Holders
63
Holders Change
-8
Holders Change %
-11.27%
% of All Funds
1.4%
Holding in Top 10
3
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.07%
New
9
Increased
25
Reduced
19
Closed
15
Calls
$348K
Puts
–
Net Calls
+$348K
Net Calls Change
+$707K

Top Buyers

Rank Fund Capital Flow
1
WCM
Wildcat Capital Management
New York
+$10.7M
2
BlackRock
BlackRock
New York
+$8.88M
3
HCM
Highline Capital Management
New York
+$5.83M
4
CI
Clal Insurance
Israel
+$4.01M
5
DG
Delek Group
Israel
+$2.87M

Top Sellers

Rank Fund Capital Flow
1
MIH
Meitav Investment House
Israel
-$7.45M
2
Millennium Management
Millennium Management
New York
-$5.55M
3
Wellington Management Group
Wellington Management Group
Massachusetts
-$928K
4
MAP
Moody Aldrich Partners
Massachusetts
-$860K
5
Renaissance Technologies
Renaissance Technologies
New York
-$793K
Name Holding Trade Value Shares
Change 		Change in
Stake
MMH
1
Menora Mivtachim Holdings
Israel
$108M – – –
CCM
2
Consonance Capital Management
New York
$65.3M – – –
Wellington Management Group
3
Wellington Management Group
Massachusetts
$41.9M -$928K -20,632 -2%
WCM
4
Wildcat Capital Management
New York
$26.4M +$10.7M +237,015 +63%
Fidelity Investments
5
Fidelity Investments
Massachusetts
$23.9M – – –
HCM
6
Highline Capital Management
New York
$19.9M +$5.83M +129,778 +39%
CS
7
Credit Suisse
Switzerland
$18.8M +$753K +16,748 +4%
MIH
8
Meitav Investment House
Israel
$18M -$7.45M -165,614 -28%
CI
9
Clal Insurance
Israel
$17.2M +$4.01M +89,262 +29%
Citadel Advisors
10
Citadel Advisors
Florida
$16.1M +$4.41K +98 +0%
BlackRock
11
BlackRock
New York
$12.9M +$8.88M +197,410 +192%
DG
12
Delek Group
Israel
$7.23M +$2.87M +63,815 +64%
Man Group
13
Man Group
United Kingdom
$5.16M +$593K +13,188 +12%
Millennium Management
14
Millennium Management
New York
$4.73M -$5.55M -123,461 -53%
SAM
15
Shikiar Asset Management
New York
$3.21M -$179K -3,975 -5%
Point72 Asset Management
16
Point72 Asset Management
Connecticut
$2.8M +$582K +12,954 +25%
State Street
17
State Street
Massachusetts
$1.69M +$120K +2,665 +7%
PFO
18
Pathstone Family Office
New Jersey
$1.67M +$1.74M +38,700 New
AA
19
ALPS Advisors
Colorado
$1.6M +$412K +9,156 +33%
USAA
20
United Services Automobile Association
Texas
$1.38M +$62.4K +1,387 +5%
AS
21
Altshuler Shaham
Israel
$1.06M +$1.11M +24,698 New
Barclays
22
Barclays
United Kingdom
$916K +$57.6K +1,281 +6%
MCM
23
McKinley Capital Management
Alaska
$798K +$17.4K +386 +2%
Swiss National Bank
24
Swiss National Bank
Switzerland
$784K +$45K +1,000 +6%
Northern Trust
25
Northern Trust
Illinois
$758K +$71.9K +1,600 +10%
1
2 3 4

URGN Hedge Fund Activity: Q4 2018 in Review

63 of the 4,489 institutional investors tracked by Wall St. Rank reported a position in UroGen Pharma (URGN) for Q4 2018, worth a combined $413M — down 12% from $469M a quarter earlier.

Sellers outnumbered buyers: 15 funds closed out of URGN and 9 opened new positions — a net loss of 6 holders — while 19 trimmed existing stakes and 25 added.

The largest buyer was Wildcat Capital Management, adding an estimated $10.7M. The largest seller was Meitav Investment House, cutting an estimated $7.45M.

  • 63 institutional investors held UroGen Pharma (URGN) as of Q4 2018, down from 71 in Q3 2018.
  • Funds reported $413M of UroGen Pharma stock for Q4 2018, down 12% quarter-over-quarter.
  • 9 funds opened new UroGen Pharma positions in Q4 2018 and 15 closed out, a net change of -6 holders.
  • The largest UroGen Pharma buyer in Q4 2018 was Wildcat Capital Management, an estimated $10.7M added.
  • The largest UroGen Pharma seller in Q4 2018 was Meitav Investment House, an estimated $7.45M sold.

Based on aggregated 13F filings for Q4 2018.